Objective: The aim of the study was to evaluate the various growth factors (GFs) released for a period of 300 minutes (which covers the maximum time needed for surgical or day care procedures) for a feasibility trial from platelet-rich fibrin releasates (PRFr). Methods: Six healthy donors were recruited and 64 mL of blood sample was withdrawn from each individual. Following the standard centrifugation protocol, platelet-rich fibrin (PRF) and PRFr were prepared. The platelet-derived growth factor-AB (PDGF-AB), insulin-like growth factor-1 (IGF-1), transforming growth factor β-1 (TGF-β1), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), basic fibroblast growth factor (b-FGF), and nerve growth factor (NGF) were evaluated in PRFr over 300 minutes after clot formation. Results: The comparison between the final released amounts and the initial content in PRFr: PDGF-AB, IGF-1, TGF-β1, VEGF, EGF, b-FGF and NGF levels were 1.7-, 4.2-, 5.7-, 2.2-, 7.7-, 3.1- and 2.2-fold higher, respectively, in the 300-minute period than in the 5-minute period. The content of GFs in the releasates at 300 minutes were significantly different from respective content at 5 minutes. Conclusion: The PRFr could be used in day-surgery procedures after formation to maximize release of GFs to the wound site, theoretically enhancing the potential for tissue healing.